Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 7/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469705 | 0.93 | ADORA3 (0.57) | ADORA3FLT3HCRTR2MAPK8 | |
| SCHEMBL275206 | 0.87 | MAPK8 (0.54) | ADORA3FLT3HCRTR2MAPK8 | |
| SCHEMBL5394394 | 0.79 | TTK (0.59) | ADORA3FLT3MAPK8 | |
| SCHEMBL19068534 | 0.78 | HCRTR2 (0.43) | ADORA3HCRTR2 | |
| SCHEMBL11940635 | 0.78 | ADORA3 (0.56) | ADORA3 | |
| SCHEMBL16041123 | 0.77 | HCRTR2 (0.42) | ADORA3FLT3HCRTR2 | |
| SCHEMBL2269579 | 0.77 | FLT3 (0.55) | ADORA3FLT3HCRTR2 | |
| SCHEMBL5394350 | 0.76 | TTK (0.55) | ADORA3FLT3 | |
| SCHEMBL8240135 | 0.76 | AURKA (0.58) | ADORA3FLT3 | |
| SCHEMBL5618657 | 0.74 | FLT3 (0.47) | ADORA3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | ADORA3 2912/4885FLT3 216/4885HCRTR2 4564/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | ADORA3 2383/4885FLT3 215/4885HCRTR2 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.